Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott A Boerner

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of the National Cancer Institute|November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Translating clinical trials into meaningful outcomesPatricia M LoRusso, Lowell E Schnipper, David J Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2012
Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshopPatricia M LoRusso, Renzo Canetta, John A Wagner, et al.
Plos One|March 17, 2015
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancerJulie L Boerner, Nicole Nechiporchik, Kelly L Mueller, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Cancer Research Communications|June 28, 2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsMichael Cecchini, Zenta Walther, Wei Wei, et al.
Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2Kimberly A Chianese-Bullock, Elizabeth M H Woodson, Huimin Tao, et al.
The Journal of Cell Biology|July 24, 2003
PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activationJill K Slack-Davis, Scott T Eblen, Maja Zecevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of the National Cancer Institute|November 22, 2012
Meta-analysis of the relationship between dose and benefit in phase I targeted agent trialsSachin Gupta, Sally Hunsberger, Scott A Boerner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2010
Translating clinical trials into meaningful outcomesPatricia M LoRusso, Lowell E Schnipper, David J Stewart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2012
Accelerating cancer therapy development: the importance of combination strategies and collaboration. Summary of an Institute of Medicine workshopPatricia M LoRusso, Renzo Canetta, John A Wagner, et al.
Plos One|March 17, 2015
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancerJulie L Boerner, Nicole Nechiporchik, Kelly L Mueller, et al.
Investigational New Drugs|January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumorsHoward A Burris, Suzanne F Jones, Daphne D Williams, et al.
Cancer Research Communications|June 28, 2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid TumorsMichael Cecchini, Zenta Walther, Wei Wei, et al.
Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2Kimberly A Chianese-Bullock, Elizabeth M H Woodson, Huimin Tao, et al.
The Journal of Cell Biology|July 24, 2003
PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activationJill K Slack-Davis, Scott T Eblen, Maja Zecevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.
Pageof 3